Skip to main content
Mylan's Neulasta biosimilar turned down by FDA

A complete response letter was issued by the FDA to Mylan regarding its marketing application for a biosimilar of Amgen's Neulasta, or pegfilgrastim. The letter said more data on manufacturing, controls and chemistry from Mylan's research partner, Biocon, was necessary.

Full Story: